Alyeska Investment Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,000,000
Closed -$56M 654
2024
Q2
$56M Buy
+2,000,000
New +$55.1M 0.32% 107
2024
Q1
Sell
-205,104
Closed -$5.9M 579
2023
Q4
$5.9M Buy
+205,104
New +$6.2M 0.04% 298
2020
Q3
Sell
-806,218
Closed -$25M 556
2020
Q2
$25M Sell
806,218
-1,499,784
-65% -$51M 0.38% 85
2020
Q1
$71.4M Buy
+2,306,002
New +$78.6M 1.42% 8
2016
Q3
Sell
-1,729,660
Closed -$57.8M 513
2016
Q2
$57.8M Buy
+1,729,660
New +$55.2M 0.54% 49
2015
Q4
Sell
-2,708,594
Closed -$80.7M 448
2015
Q3
$80.7M Buy
2,708,594
+1,080,754
+66% +$34.7M 0.95% 11
2015
Q2
$51.8M Buy
1,627,840
+429,905
+36% +$14M 0.59% 36
2015
Q1
$39.5M Buy
+1,197,935
New +$38.1M 0.55% 40
2014
Q2
Sell
-1,059,867
Closed -$32.3M 445
2014
Q1
$32.3M Buy
+1,059,867
New +$31.6M 0.89% 16
2013
Q3
Sell
-13,080
Closed -$348K 337
2013
Q2
$348K Buy
+13,080
New +$361K 0.02% 260

Other funds holding PFE

Alyeska Investment Group's PFE Position: Q3 2024 in Review

Alyeska Investment Group sold out of Pfizer (PFE) in Q3 2024, closing a stake of 2,000,000 shares — an estimated $56M sold.

Alyeska Investment Group first reported a position in PFE in Q2 2013 and held it in 10 quarters. The position peaked at $80.7M in Q3 2015. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • Alyeska Investment Group reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 2,000,000 Pfizer shares in Q3 2024, an estimated $56M.
  • Alyeska Investment Group first reported a position in Pfizer in Q2 2013 and held it in 10 quarters.
  • Alyeska Investment Group's Pfizer position peaked at $80.7M in Q3 2015.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.